A proposal of XXXX optimal dosing in living related liver transplantations.

@entity1 @entity500 @entity23827 @entity281 @entity1800 @entity134 @entity2834 @entity1140 @entity3307
We analyzed the relation between @entity1140 trough levels (ELISA: @entity1 1-41, IMx: @entity1 42-70) and rejection and/or @entity1800 episodes, retrospectively, in the first 70 consecutive cases of living related liver transplantation. Twenty @entity1 (28.6%) had rejection episodes. Of the 13 @entity1 who had evidence of rejection during the first 3 months, 6 @entity1 without @entity281 and 7 @entity1 with @entity1800 showed low concentrations of @entity1140 (< 5 ng/ml). Twelve @entity1 were treated and improved with high dose @entity134 administration and an increase in the @entity1140 dosage. One @entity1 died of refractory rejection. Nine @entity1 had evidence of rejection after the first 3 months. In 3 @entity1 , weaning from @entity1140 initiated the rejection episodes. Five @entity1 repeated rejection and 4 @entity1 required a third immunosuppressant ( @entity500 ). @entity1800 included @entity2834 (11 cases), EBV (13 cases), @entity23827 cases), and @entity3307 case). Excess immunosuppression might have been the cause, but no clear correlation was found. We propose that the optimal dosage of @entity1140 obtained by monitoring the trough levels using the IMx method should maintain a 10-20 ng/ml level during the first month, and a 5-10 ng/ml level at the second and third months.
